{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+High+Cancers&page=3", "query": { "condition": "Microsatellite High Cancers", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+High+Cancers&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+High+Cancers&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T18:16:05.864Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "INCAGN01949", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2017-10-09", "completion_date": "2019-09-17", "has_results": true, "last_update_posted_date": "2022-09-27", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03241173" }, { "nct_id": "NCT03436563", "title": "M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "High-Frequency Microsatellite Instability", "Metastatic Malignant Solid Neoplasm", "Rectal Adenocarcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colon Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Anti-PD-L1/TGFbetaRII Fusion Protein M7824", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-03-07", "completion_date": "2023-08-08", "has_results": true, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436563" }, { "nct_id": "NCT05909995", "title": "Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Hepatocellular Carcinoma (HCC)", "Renal Cell Carcinoma (RCC)", "Microsatellite Instability - High (MSI-H)", "Mismatch Repair Deficient (dMMR)", "Colorectal Carcinoma (CRC)" ], "interventions": [ { "name": "INCB 99280 with Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2023-08-29", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2025-02-18", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 5, "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05909995" }, { "nct_id": "NCT05572684", "title": "A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Microsatellite Instability Low", "Microsatellite Instability High", "Microsatellite Stable", "Ovarian Cancer", "Gastric Cancer", "Colo-rectal Cancer", "Esophageal Cancer", "Endometrial Cancer", "Head Neck Cancer", "Cervical Cancer", "Lung Cancer" ], "interventions": [ { "name": "NC410", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NextCure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2022-10-06", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 17, "location_summary": "Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Edgewood", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05572684" }, { "nct_id": "NCT04098068", "title": "Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Tumor Mutation Burden", "High TMB (Tumor Mutation Burden)", "MSS (Microsatellite Stable)" ], "interventions": [ { "name": "MK-3475", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-01-25", "completion_date": "2025-02-05", "has_results": true, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 3, "location_summary": "Baltimore, Maryland • New York, New York • Columbus, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04098068" }, { "nct_id": "NCT03866239", "title": "A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cibisatamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2019-05-07", "completion_date": "2024-03-13", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 7, "location_summary": "Los Angeles, California • Santa Monica, California • Stanford, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03866239" }, { "nct_id": "NCT05838768", "title": "Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers" ], "interventions": [ { "name": "HRO761", "type": "DRUG" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 123, "start_date": "2023-06-27", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05838768" }, { "nct_id": "NCT03767348", "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Microsatellite Instability-High (MSI-H)", "Non-melanoma Skin Cancer (NMSC)", "Cutaneous Melanoma" ], "interventions": [ { "name": "RP1", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2017-09-20", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03767348" }, { "nct_id": "NCT03832569", "title": "Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Solid Tumors", "Identified by NGS, PCR or IHC" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2019-02-20", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03832569" }, { "nct_id": "NCT03495674", "title": "Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "High-Frequency Microsatellite Instability", "Mismatch Repair Gene Mutation", "Mutation-Negative Lynch Syndrome", "Mutation-Positive Lynch Syndrome" ], "interventions": [ { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Informational Intervention", "type": "OTHER" }, { "name": "Monitoring Device", "type": "DEVICE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "DEVICE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 21, "start_date": "2018-04-04", "completion_date": "2024-01-02", "has_results": false, "last_update_posted_date": "2024-01-05", "last_synced_at": "2026-10-13T18:16:05.864Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03495674" } ] }